HC Wainwright & Co. Reiterates Buy on Janux Therapeutics, Maintains $35 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Janux Therapeutics (NASDAQ:JANX) and maintained a $35 price target.
July 18, 2023 | 10:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Janux Therapeutics (NASDAQ:JANX) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $35.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $35 indicates the firm's continued confidence in the company's potential. This could lead to increased investor interest and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100